Research Article
American Journal of BioMedicine
Volume 11, Issue 4, 2023, Pages 172-185 
10.18081/2333-5106/2023.11/172
Dmytro M. Hladkykh 1 
, Victoria Oleshko , Nataliya Berladir 
Received 30 May 2023; revised 22 August 2023; accepted 22 September 2023; published 22 November 2023
Abstract
About 10–15% of patients with early-stage and 15-30% with relapsed Hodgkin lymphoma after primary conventional treatment. Despite the approval of novel therapies, autologous stem cell transplantation (ASCT) remains the standard of care in these patients. However, up to half of transplanted individuals may relapse. Pembrolizumab is an FDA-approved monoclonal antibody directed against programmed cell death protein 1 (PD-1), it has received approval for the treatment of solid cancer and showed increased progression-free survival in high-risk patients with relapsed Hodgkin lymphoma receiving autologous stem cell transplantation. This study aims to investigate the role of relapsed Hodgkin lymphoma after using Pembrolizumab. This study was conducted for 80 patients with relapsed Hodgkin lymphoma who received Pembrolizumab and 50 patients had completed treatment with 40% complete response. In conclusion, Pembrolizumab showed a good response in patients with relapsed Hodgkin lymphoma.
Keywords: Pembrolizumab; Relapsed Hodgkin lymphoma; ASCT
Copyright © 2023 Hladkykh, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cited by CrossRef (0)
Cited by Scopus (2)
| 1. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-854. https://doi.org/10.1016/j.hoc.2007.06.011 |
||||
| 2. Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (CHL) after autologous transplantation: 5-year overall survival from the phase 2 CheckMate 205 study. Hematol Oncol. 2021;39(suppl 2):122-125. | ||||
| 3. Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125-2132. https://doi.org/10.1200/JCO.2016.72.1316 |
||||
| 4. Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144-1153. https://doi.org/10.1182/blood.2019000324 |
||||
| 5. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkmate 205 trial. J Clin Oncol. 2018;36(14):1428-1439. https://doi.org/10.1200/JCO.2017.76.0793 |
||||
| 6. Hoppe RT, Advani RH, Ai WZ, et al. NCCN Guidelines® insights: Hodgkin lymphoma, version 2.2022. J Natl Compr Canc Netw. 2022;20(4):322-334. | ||||
| 7. Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733-3739. https://doi.org/10.1200/JCO.2016.67.3467 |
||||
| 8. Moskowitz AJ, Hamlin PA Jr., Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31(4):456-460. https://doi.org/10.1200/JCO.2012.45.3308 |
||||
| 9. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85(5):320-324. https://doi.org/10.1002/ajh.21664 |
||||
| 10. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183-2189. https://doi.org/10.1200/JCO.2011.38.0410 |
||||
| 11. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-623. https://doi.org/10.1182/blood.V97.3.616 |
||||
| 12. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001;113(1):161-171. https://doi.org/10.1046/j.1365-2141.2001.02714.x |
||||
| 13. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13(10):1628-1635. https://doi.org/10.1093/annonc/mdf221 |
||||
| 14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. https://doi.org/10.1200/JCO.2006.09.2403 |
||||
| 15. Conceição MS, Chetterje ED, Gupta M, et al. Complete remission of Hodgkin Lymphoma after a concurrent infection with COVID-19: systematic review and meta-analysis. Muthanna Medical Journal. 2022;6(1): 57-67. https://doi.org/10.52113/1/1/2022-57-67 |
||||
| 16. Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol. 2002;13(10):1628-1635. https://doi.org/10.1093/annonc/mdf221 |
||||
| 17. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. Br J Haematol. 2001;113(1):161-171. https://doi.org/10.1046/j.1365-2141.2001.02714.x |
||||
| 18. Agnello D, Lankford CS, Bream J, et al. Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. J Clin Immunol. 2003;23:147-161. https://doi.org/10.1023/A:1023381027062 |
||||
| 19. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high- Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616-623. https://doi.org/10.1182/blood.V97.3.616 |
||||
| 20. Josting A, Engert A, Diehl V, et al. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol. 2002;13(suppl 1)112-116. https://doi.org/10.1093/annonc/13.S1.112 |
||||
| 21. Seftel M, Rubinger M. The role of hematopoietic stem cell transplantation in advanced Hodgkin lymphoma. Transfus Apheresis Sci. 2007;37:49-56. https://doi.org/10.1016/j.transci.2007.04.005 |
||||
| 22. Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma. Haematologica. 2010;95:1496-1502. https://doi.org/10.3324/haematol.2009.019943 |
||||
| 23. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res. 2011;17:6118-6124. https://doi.org/10.1158/1078-0432.CCR-11-0482 |
||||
File and statistics
Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.